Supreme Court: Parents’ Loss Cannot Be Measured With Arithmetical Precision  ||  Supreme Court: Registered Sale Deed Remains Valid Despite Minor Attestation Discrepancies  ||  Calcutta High Court: Section 107 BNSS Property Attachment Cannot be Used as a Recovery Tool  ||  Ker HC: Elected Representatives Must Swear by God or Affirm, Cannot Invoke Specific Deities in Oath  ||  Rajasthan High Court: Ward Delimitation Must Rely on Population, Not Voter Count  ||  SC: Readiness for Agreement Execution Must be Proven From Agreement Date, Not Only After Suit Filing  ||  Supreme Court: Long Gap Without Similar Criminal Conduct May Mitigate Sentence  ||  Supreme Court: Loss of Right Leg Constitutes 100% Functional Disability for a Mason  ||  Del HC Orders Fresh All India Tennis Association Elections by Sept 30, Sets Timeline for Amendments  ||  Bombay High Court Permits 26-Week Pregnancy Termination Due to Fetal Anomalies, Financial Hardship    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved